Cardiovascular · AntihypertensiveSafety Signalregulatorynear-term

Crescent Pharma recalls Ramipril 2.5mg due to packaging error

Importance8/ 10

ActionInvestigate

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Crescent Pharma Limited5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 6:34:00 PM

Assessment confidence: 60% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The recall of Ramipril 2.5mg capsules due to a packaging error poses significant risks to patient safety and could lead to reputational damage for Crescent Pharma. This situation necessitates a thorough investigation to understand the potential implications for regulatory compliance and market positioning. Regulatory context from MHRA (Guidance: Best practice in the labelling and packaging of medicines) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the potential impact on sales and consider strategies to mitigate reputational damage. The strongest clinical anchor is Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Cardiovascular · Antihypertensive, 4 regulatory and 3 competitive items passed relevance filtering for Crescent Pharma Limited.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation.

Regulatory Outlook

Regulatory risk is concentrated around Guidance: Best practice in the labelling and packaging of medicines (MHRA). Regulatory pathway relevance (label). Relevant agencies in corpus: MHRA, FDA. The packaging error raises serious compliance concerns that could lead to increased scrutiny from regulatory authorities, affecting future approvals and market access.

Key Risks

Elevated high regulatory exposure for Crescent Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The recall may lead to a temporary decline in sales and market share for Crescent Pharma, particularly if adverse effects are reported, impacting their competitive standing in the antihypertensive segment.
This guidance explains the legal framework for labelling and packaging as described in UK legislation and gives best practice for producing medicines labelling and packaging.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
Upside for Crescent Pharma Limited may improve if Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain. (PubMed) delivers favorable follow-through.
Portfolio and strategy teams should assess the potential impact on sales and consider strategies to mitigate reputational damage.

What Would Change This Assessment

This becomes more urgent if Monitor for reports of adverse events related to the incorrect dosage and any regulatory responses.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Guidance: Best practice in the labelling and packaging of medicines
MHRAhigh relevance
Regulatory pathway relevance (label)
FDA document
View source
Medicines: packaging, labelling and patient information leaflets
MHRAhigh relevance
Regulatory pathway relevance (label)
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of ultrasound ablation for uterine fibroids in patients with abdominal surgical scars on the acoustic pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Crescent Pharma Limited

Commercial impact

medium

The recall may lead to a temporary decline in sales and market share for Crescent Pharma, particularly if adverse effects are reported, impacting their competitive standing in the antihypertensive segment.

Regulatory impact

high

The packaging error raises serious compliance concerns that could lead to increased scrutiny from regulatory authorities, affecting future approvals and market access.

What to watch

Monitor for reports of adverse events related to the incorrect dosage and any regulatory responses.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.